Clinical Value of Ezrin Expression in Primary Osteosarcoma

Kim, Chan; Shin, Eunah; Hong, Soojung; Chon, Hong Jae; Kim, Hye Ryun; Ahn, Joong Bae; Hong, Min Hee; Yang, Woo Ick; Roh, Jae Kyung; Rha, Sun Young

doi:10.4143/crt.2009.41.3.138

Cited by 40 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,26 Ezrin is commonly considered to play a role as "key protein" in the invasion and metastasis of a wide variety of tumors. 7,[27][28][29] The present study showed that overexpression of ezrin promoted gastric cancer cell invasion, whereas inactivating ezrin function with small interference RNA caused reduced cell invasion, indicating a potential role of ezrin in regulating the progression to invasive gastric cancer. Similar reports have shown that interference of ezrin expression 30 or an ezrin deletion mutant comprising 146 N-terminal amino acids 31 blocks metastasis of esophageal squamous cancer and melanoma cells both in vivo and in vitro.…”

Section: Discussionmentioning

confidence: 53%

Knockdown ofezrinvia RNA interference suppressesHelicobacter pylori-enhanced invasion of gastric cancer cells

Fan

Chen²,

Lan³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 53%

Knockdown ofezrinvia RNA interference suppressesHelicobacter pylori-enhanced invasion of gastric cancer cells

Fan

Chen²,

Lan³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Of those, 16 reports were excluded: six due to reviews, nine due to lack of any informative clinical data, and one due to it is overlapping with another study (Figure 1). In all, seven independent eligible studies (Kim et al, 2007;Salas et al, 2007;Xu-dong et al, 2008;Kim et al, 2009;Xu-Dong et al, 2009;Boldrini et al, 2010;Wang et al, 2011), which had data on 2-year survival and enrolled a total of 318 patients, were included in the quantitative synthesis. The mean or median age of patients included in each study ranged from 15 to 22 years across the eligible studies; these populations were young.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Five studies (Kim et al, 2007;Xu-dong et al, 2008;Kim et al, 2009;Xu-Dong et al, 2009;Boldrini et al, 2010) used IHC to determine Ezrin status, whereas one study (Wang et al, 2011) used RT-PCR and one study (Salas et al, 2007) used both IHC and RT-PCR determinations. Two studies (Kim et al, 2009;Xu-Dong et al, 2009) used more than 10% cut-off Ezrin positivity, whereas two studies (Salas et al, 2007;Boldrini et al, 2010) used more than 1% cut-off Ezrin positivity and two studies (Kim et al, 2007;Xu-dong et al, 2008) used more than 0% cut-off Ezrin positivity.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Recent studies have come to inconsistent conclusions. In some studies, the increased levels of Ezrin , Yang Wu 1,2 protein at diagnosis resulted in an association with a worse clinical outcome (Kim et al, 2007;Xu-dong et al, 2008;Kim et al, 2009;Xu-Dong et al, 2009), whereas other reports either did not show any correlation between Ezrin and prognosis (Salas et al, 2007, Boldrini et al, 2010 or indicated a positive prognostic value for increased Ezrin expression at diagnosis (Wang et al, 2011). Most studies had a limited sample size, thus a quantitative synthesis using rigorous methods would be important to perform.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis

Wang

He²,

Zhao³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Various studies examining the relationship between Ezrin overexpression and response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results. We accordingly conducted a meta-analysis of 7 studies (n = 318 patients) that evaluated the correlation between Ezrin and histologic response to chemotherapy and clinical prognosis (death). Data were synthesized in receiver operating characteristic curves and with fixed-effects and random-effects likelihood ratios and risk ratios. Quantitative synthesis showed that Ezrin is not a prognostic factor for the response to chemotherapy. The positive likelihood ratio was 0.538 (95% confidence interval [95% CI], 0.296-0.979; random-effects calculation), and the negative likelihood ratio was 2.151 (95% CI, 0.905-5.114; random-effects calculations). There was some between-study heterogeneity, but no study showed strong discriminating ability. Conversely, Ezrin positive status tended to be associated with a lower 2-year survival (risk ratio, 2.45; 95% CI, 1.26-4.76; random-effects calculation) with some between-study heterogeneity that disappeared when only studies that employed immunohistochemistry were considered (risk ratio, 2.97; 95% CI, 2.01-4.40; fixed-effects calculation). To conclude, Ezrin is not associated with the histologic response to chemotherapy in patients with osteosarcoma, whereas Ezrin positivity was associated with a lower 2-year survival rate regarding risk of death at 2 years. Expression change of Ezrin is an independent prognostic factor in patients with osteosarcoma.

show abstract

“…It is therefore generally considered to be one of the predictive prognostic biomarkers in various cancer types, including osteosarcoma, breast cancer, colorectal carcinoma, soft tissue sarcoma and serous ovarian carcinoma (3)(4)(5)(6)(7)(8)(9)(10). Ezrin protein is a member of the ERM (ezrin-radixin-moesin) group of proteins that are produced from the VIL2 (Ctytovillin) gene, which is a cyclic AMP-dependent protein kinase anchoring protein.…”

Section: Introductionmentioning

confidence: 99%

Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors

et al. 2011

View full text Add to dashboard Cite

Abstract. Membrane-cytoskeleton linker organizer ezrin is a member of the ERM (ezrin-radixin-moesin) protein family. It has been suggested as an important element in the oncogenic process, particularly in conferring a metastatic ability on tumor cells. We hypothesized that the KIT oncogenic form is one of the proteins that modulates expression of the ezrin protein via phosphorylated ezrin at different residues; furthermore, it may interact with the protein merlin, and promoting tumor development via the PI3K or MAPK pathway. In the present study, we observed that differential expression of ezrin was a common feature in gastrointestinal stromal tumors (GISTs). We further demonstrated that cases exhibiting expression of phosphorylated Thr567 in the ezrin protein were associated with immunoactivities of KIT and merlin expression (p=0.039 and 0.013, respectively). In conclusion, GISTs harbor activation of KIT protein may induce phosphorylation of the downstream protein ezrin at certain residues, thereby triggering subsequent signal transduction cascades and driving downstream pathways of tumor progression. However, a larger series of tumor samples should be analyzed in future studies, as well as the identification of phosphorylated sites to determine the role of ezrin in tumor progression thus shedding light on clinical outcomes.

show abstract

Clinical Value of Ezrin Expression in Primary Osteosarcoma

Cited by 40 publications

References 22 publications

Knockdown ofezrinvia RNA interference suppressesHelicobacter pylori-enhanced invasion of gastric cancer cells

Knockdown ofezrinvia RNA interference suppressesHelicobacter pylori-enhanced invasion of gastric cancer cells

Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis

Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors

Contact Info

Product

Resources

About